Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study

Respiratory Research

Volumn 12, Issue 1, 2011, Pages

  Mannino, David M ^a,b   Diaz Guzman, Enrique ^b   Buist, Sonia ^c  

^a UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Bronchodilator responsiveness; COPD; Epidemiology; Mortality

Indexed keywords

IPRATROPIUM BROMIDE; BRONCHODILATING AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY HEIGHT; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; ETHNICITY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; POPULATION RESEARCH; POST BRONCHODILATOR LUNG FUNCTION; PRE BRONCHODILATOR LUNG FUNCTION; PREDICTION; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SMOKING HABIT; SURVIVAL ANALYSIS; SURVIVAL PREDICTION; SURVIVAL RATE; AGED; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; LUNG; METHODOLOGY; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTIVE VALUE;

ADULT; AGED; BRONCHODILATOR AGENTS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS;

EID: 80053916345     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/1465-9921-12-136     Document Type: Article

References (32)

1. Mannino DM, Buist AS: Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007, 370:765-773.
2. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC: Chronic obstructive pulmonary disease surveillance--United States, 1971-2000. MMWR Surveill Summ 2002, 51:1-16.
3. Minino AM, Xu J, Kochanek KD: Death in the United States, 2008. National Vital Statistics Reports 2010, 59:1-72.
4. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van WC, et al.: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555.
5. Celli BR, MacNee W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946.
6. Wenzel SE: Asthma: defining of the persistent adult phenotypes. Lancet 2006, 368:804-813.
7. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, et al.: Interpretative strategies for lung function tests. Eur Respir J 2005, 26:948-968.
8. Johannessen A, Lehmann S, Omenaas ER, Eide GE, Bakke PS, Gulsvik A: Post-bronchodilator spirometry reference values in adults and implications for disease management. Am J Respir Crit Care Med 2006, 173:1316-1325.
9. Johannessen A, Omenaas ER, Bakke PS, Gulsvik A: Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study. Thorax 2005, 60:842-847.
10. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2008 Update) [ http://www.goldcopd.org ]
11. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC: Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003, 58:388-393.
12. Mannino DM, Doherty DE, Buist AS: Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006, 100:115-122.
13. Engstrom G, Hedblad B, Nilsson P, Wollmer P, Berglund G, Janzon L: Lung function, insulin resistance and incidence of cardiovascular disease: a longitudinal cohort study. J Intern Med 2003, 253:574-581.
14. Mannino DM, Buist AS, Vollmer WM: Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function? Thorax 2007, 62:237-241.
15. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Enright PL, Kanner RE, O'Hara P, et al.: Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994, 272:1497-1505.
16. Connett JE, Kusek JW, Bailey WC, O'Hara P, Wu M: Design of the Lung Health Study: a randomized clinical trial of early intervention for chronic obstructive pulmonary disease. Control Clin Trials 1993, 14:3S-19S.
17. Anthonisen NR, Lindgren PG, Tashkin DP, Kanner RE, Scanlon PD, Connett JE: Bronchodilator response in the lung health study over 11 yrs. Eur Respir J 2005, 26:45-51.
18. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE: The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005, 142:233-239.
19. Hankinson JL, Odencrantz JR, Fedan KB: Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med 1999, 159:179-187.
20. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS: Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study27. Am J Respir Crit Care Med 2000, 161:381-390.
21. Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist AS, Calverley PMA, Chavannes N, Dillard T, Fahy B, et al.: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. European Respiratory Journal 2004, 23:932-946.
22. Sterk PJ: Let's not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1. Eur Respir J 2004, 23:497-498.
23. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW: Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003, 58:659-664.
24. Perez-Padilla R, Hallal PC, V+ízquez-Garc+ia JC, Mui+o A, M+íquez Ma, L+pez MaV, de Oca MaM, T+ílamo C, Valdivia G, Pertuz J, et al.: Impact of Bronchodilator Use on the Prevalence of COPD in Population-Based Samples. COPD: Journal of Chronic Obstructive Pulmonary Disease 2007, 4:113-120.
25. Hansen EF, Phanareth K, Laursen LC, Kok-Jensen A, Dirksen A: Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 159:1267-1271.
26. Burrows B: Predictors of loss of lung function and mortality in obstructive lung diseases. Eur Respir Rev 1991, 1:340-345.
27. Postma DS, de VK, Koeter GH, Sluiter HJ: Independent influence of reversibility of air-flow obstruction and nonspecific hyperreactivity on the long-term course of lung function in chronic air-flow obstruction. Am Rev Respir Dis 1986, 134:276-280.
28. Kanner RE: The relationship between airways responsiveness and chronic airflow limitation. Chest 1984, 86:54-57.
29. Tashkin DP, Celli B, Decramer M, Liu D, Burkhart D, Cassino C, Kesten S: Bronchodilator responsiveness in patients with COPD. Eur Respir J 2008, 31:742-750.
30. Lederer DJ, Enright PL, Kawut SM, Hoffman EA, Hunninghake G, van Beek EJ, Austin JH, Jiang R, Lovasi GS, Barr RG: Cigarette smoking is associated with subclinical parenchymal lung disease: the Multi-Ethnic Study of Atherosclerosis (MESA)-lung study. Am J Respir Crit Care Med 2009, 180:407-414.
31. Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA, MacNee W, Miller BE, Rennard S, Silverman EK, et al.: Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010, 11:122.
32. Han MK, Agusti A, Calverley PM, Celli BR, Criner G, Curtis JL, Fabbri LM, Goldin JG, Jones PW, MacNee W, et al.: Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med 2010, 182:598-604.